Category: Wall Street BeatSyndicate content

St. Jude Medical settles Riata, shareholder suits for $64m

February 27, 2015 by Brad Perriello

St. Jude Medical agrees to settle product liability lawsuits filed over its recalled Riata defibrillator leads and a class-action shareholder's suit accusing it of inflating results for its 2009 3rd quarter.

St. Jude Medical settles Riata, shareholder lawsuits for $64m

Bellerophon slides 21% after IPO

February 26, 2015 by Mark Hollmer

Bellerophon Therapeutics shares are down nearly 21% since their $12-per-share debut earlier this month.

Bellerophon shares down 21%

Bellerophon Therapeutics (NSDQ:BLPH) shares are down nearly 21% since its IPO 2 weeks ago, when the stock in the New Jersey-based drug-device company opened at $10 per share, down 16.7% right out of the gate.

ViewRay registers for initial public offering worth up to $69 million | Medtech Wall Street news for the week of February 23, 2015

February 26, 2015 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: ViewRay registers for $69m IPO; Bellerophon prices $60m IPO low, issues more shares; Cutera expands stock buyback to $40M

ViewRay registers for $69m IPO

February 16, 2015 by Brad Perriello

ViewRay registers for $69m IPO

Cutera expands stock buyback to $40M

February 19, 2015 by Val Kennedy

Cutera's board of directors has expanded the company's stock buyback plan from $10 million to $40 million, the company announced Wednesday.

Cutera narrows losses but misses expectations in Q2

Cutera's (NSDQ:CUTR) board of directors has expanded the company's stock buyback plan from $10 million to $40 million, the company announced Wednesday.

ViewRay registers for $69m IPO

February 16, 2015 by Brad Perriello

ViewRay registers for an initial public offering worth up to $69 million for its MRIdian cancer detection and radiation treatment device.

ViewRay registers for $69m IPO

ViewRay last week said it plans to raise up to $69 million in an initial public offering for its MRIdian system, which it bills as "the 1st and only MRI-guided radiation therapy system that images and treats cancer patients simultaneously."

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Bellerophon prices $60m IPO low, issues more shares

February 13, 2015 by Brad Perriello

Bellerophon Therapeutics prices its initial public offering under range, but issues a million more shares than planned, for a gross take of $60 million.

Bellerophon prices $60m IPO low, issues more shares

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Zimmer revises Biomet bid for EU regulators

February 10, 2015 by Brad Perriello

Zimmer revises its $13 billion bid for crosstown rival Biomet in a further effort to mollify European anti-trust regulators, saying it thinks the deal is still on track to close during the 1st quarter.

Zimmer revises Biomet bid for EU regulators

Get the complete picture with a MassDevice Plus membership. Registered users can login here.